内容紹介
A Patient with Recurrent Ovarian Clear Cell Adenocarcinoma and Chronic Kidney Disease Exhibited Complete Response to Paclitaxel plus Carboplatin
Summary
A 41-year-old woman receiving hemodialysis 3 times a week for chronic kidney disease caused by interstitial nephritis was referred to our hospital because of a pelvic mass and subsequently underwent primary surgery. The patient was diagnosed with FIGO stageⅠc(b)clear cell adenocarcinoma. She did not receive postoperative chemotherapy. However, 9 months after surgery, ascites and a pelvic mass developed, on the basis of which recurrence was confirmed. She received combination chemotherapy with paclitaxel plus carboplatin(TC). Paclitaxel was administered at 175 mg/m2, and the carboplatin dosage was calculated by the Calvert formula. The glomerular filtration rate was considered to be 0, and the target area under the plasma concentration versus time curve was 5. Hemodialysis was performed 24 hours after the infusion of carboplatin. After 6 courses of combination chemotherapy, complete response was confirmed by computed tomography. The patient developed grade 3 neutropenia, grade 1 sensory neuropathy, and grade 2 alopecia, but the other adverse events were mild. In conclusion, TC combination chemotherapy was well tolerated and generated a good response in a patient with recurrent ovarian clear cell adenocarcinoma who was receiving hemodialysis for chronic kidney disease.
要旨
症例は41歳,女性。間質性腎炎後の慢性腎不全で8年前から週3回の血液透析を受けている。左側卵巣癌疑いの術前診断にて,卵巣癌基本手術およびstaging laparotomyを施行した。術後病理診断は卵巣癌Ⅰc(b)期(明細胞腺癌)であるも,術後補助化学療法は行わなかった。その後9か月後に腹腔内に再発し,パクリタキセル・カルボプラチン(TC)療法を6コース施行した。パクリタキセル175 mg/m2とカルボプラチンAUC5を開始した。血液透析は約24時間後に行った。重篤な有害事象は認めず,TC療法6コース施行し,再発病変はcomplete responseを得られ,無病生存状態を確認した。
目次
Summary
A 41-year-old woman receiving hemodialysis 3 times a week for chronic kidney disease caused by interstitial nephritis was referred to our hospital because of a pelvic mass and subsequently underwent primary surgery. The patient was diagnosed with FIGO stageⅠc(b)clear cell adenocarcinoma. She did not receive postoperative chemotherapy. However, 9 months after surgery, ascites and a pelvic mass developed, on the basis of which recurrence was confirmed. She received combination chemotherapy with paclitaxel plus carboplatin(TC). Paclitaxel was administered at 175 mg/m2, and the carboplatin dosage was calculated by the Calvert formula. The glomerular filtration rate was considered to be 0, and the target area under the plasma concentration versus time curve was 5. Hemodialysis was performed 24 hours after the infusion of carboplatin. After 6 courses of combination chemotherapy, complete response was confirmed by computed tomography. The patient developed grade 3 neutropenia, grade 1 sensory neuropathy, and grade 2 alopecia, but the other adverse events were mild. In conclusion, TC combination chemotherapy was well tolerated and generated a good response in a patient with recurrent ovarian clear cell adenocarcinoma who was receiving hemodialysis for chronic kidney disease.
要旨
症例は41歳,女性。間質性腎炎後の慢性腎不全で8年前から週3回の血液透析を受けている。左側卵巣癌疑いの術前診断にて,卵巣癌基本手術およびstaging laparotomyを施行した。術後病理診断は卵巣癌Ⅰc(b)期(明細胞腺癌)であるも,術後補助化学療法は行わなかった。その後9か月後に腹腔内に再発し,パクリタキセル・カルボプラチン(TC)療法を6コース施行した。パクリタキセル175 mg/m2とカルボプラチンAUC5を開始した。血液透析は約24時間後に行った。重篤な有害事象は認めず,TC療法6コース施行し,再発病変はcomplete responseを得られ,無病生存状態を確認した。